Insulet Corp PODD

Morningstar Rating
Add To Portfolio
$243.26
13.52 | 5.27%
USD | NASDAQ | Prices updated as of Apr 04, 2025, 2:58 PM EST | BATS BZX Real-Time Price
  • Last Close
    257
  • Sector
    Healthcare
  • Industry
    Medical Devices
  • Investment Style
    Mid Growth
  • Market Cap
    17.0432 Bil
  • Forward Div Yield
  • Trailing Div Yield
  • Price/Sales
    10.27
  • Price/Book
    16.72
  • Beta (5-Year)
    1.30
  • Consensus Forward P/E
    68.49
  • Trailing 12-mo Rev
    2.07

Morningstar's Analysis

Valuation Feb 28, 2025
Currency in USD
Is it the right time to buy or sell?
Fair ValueLearn Moreplay
1-Star Price
Premium
Economic Moat
Premium
5-Star Price
Premium
Capital Allocation
Premium
Medical Device Industry: Swept Up in the Tariffs, Diabetes Device Makers Bear the Brunt
Author Photo
Debbie S. Wang
Senior Equity Analyst
Analyst Note | by Debbie S. Wang Updated Apr 03, 2025

Despite intensive medtech industry lobbying to secure a carve-out from the Trump administration’s expansive tariffs on all countries, medical devices have been swept up in the tariff net.

Business Strategy and Outlook | by Debbie S. Wang Updated Feb 28, 2025

With little direct competition in patch pumps, Insulet has been able to convert more users, especially patients on multiple daily injections, to its innovative, tubeless insulin pump. The firm has carved a path to meaningful profitability gains.

Until Insulet's Omnipod came on the market at the end of 2005, all insulin pumps consisted of a contro

Morningstar Fair Value Estimate
The Morningstar Fair Value Estimate guides investors to the long-term, intrinsic value of a stock, helping them see beyond the present market price.

Show me how fair value is derived (00:41)

Morningstar calculates the fair value estimate of a company based on a projection of how much cash the company will generate in the future. Morningstar analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. The analyst discounts future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights.

The Morningstar Fair Value Estimate is a projection/opinion and not a statement of fact. If Morningstar's base-case assumptions are true the market price will converge on Morningstar's fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in the future and is no indication of future performance.

Morningstar Equity Research Methodology

Price vs. Fair Value

 
Price/Fair Value
Total Return %
Index Total Return %
2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 YTD
-17.91 -0.34 83.12 14.96 115.83 49.32 4.08 10.64 -26.30 20.32 -1.64
0.69 12.44 21.47 -5.05 31.22 20.90 25.78 -19.43 26.44 24.09 -8.35

Related

Morningstar Research
© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy       Disclosures        Accessibility